What's in Elizabeth Berry-Kravis's pipeline?

Elizabeth Berry-Kravis has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Elizabeth Berry-Kravis's portfolio?

Top competitors by shared drug class: Clinical Academic Center (2CA-Braga).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/elizabeth-berry-kravis.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Elizabeth Berry-Kravis — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Elizabeth Berry-Kravis pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
5-Hydroxytryptophan	5-Hydroxytryptophan	marketed	Serotonin precursor / amino acid supplement	Aromatic amino acid decarboxylase (enzyme substrate); indirect serotonin system modulation	Psychiatry / Neurology / Sleep Medicine

Therapeutic area mix

Psychiatry / Neurology / Sleep Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Clinical Academic Center (2CA-Braga) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Elizabeth Berry-Kravis:

Cite this brief

Drug Landscape (2026). Elizabeth Berry-Kravis — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/elizabeth-berry-kravis. Accessed 2026-05-16.